Latest / Stock Movers / Marvell Rallies on S&P Add; Micron Rebounds; Lilly Gains on Obesity Drugs
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 1: Let's take a look at some stocks on the move today.
- 0:18Speaker 1: I'm Nathan Hager, joined by Bloomberg's Dan Curtis, as we
- 0:21Speaker 1: wait for some changes to come to the S and
- 0:23Speaker 1: P five hundred. No, no, not SpaceX, but some other
- 0:27Speaker 1: stocks are getting added to the index and they are
- 0:29Speaker 1: moving off the back of it.
- 0:30Speaker 3: Good morning Dan, Good morning Nathan.
- 0:32Speaker 2: That's right.
- 0:32Speaker 3: We'll have to wait a while for SpaceX, but Marvel
- 0:34Speaker 3: and Flex are both going to be added to the
- 0:36Speaker 3: S and P five hundred. That has pushed those shares higher,
- 0:39Speaker 3: with Marvel underticker MRVL up over seven percent in pre
- 0:44Speaker 3: market and Flex FLX up nearly three percent. The move comes.
- 0:49Speaker 3: The move was announced Friday after the close, and the
- 0:52Speaker 3: changes will take place before the market open on June
- 0:54Speaker 3: twenty second. But with the inclusion comes trillions of dollars
- 0:58Speaker 3: that track the S and P five hundred, so markets
- 1:00Speaker 3: tend to front run this on the expectation that a
- 1:02Speaker 3: law of funds will have to buy it because they
- 1:04Speaker 3: are trying to replicate the performance of the S and
- 1:06Speaker 3: P five hundred. That's really lifting the shares up this morning.
- 1:10Speaker 3: And this is again off the back of the AI
- 1:12Speaker 3: trade that we can't get away from. Marvel is a
- 1:15Speaker 3: chip designer, Flex is an AI infrastructure company. Marvel up
- 1:18Speaker 3: over two hundred percent year to date, just getting big
- 1:21Speaker 3: enough to be added to the index.
- 1:22Speaker 1: Well, we're seeing some of that AI trade bounce back
- 1:25Speaker 1: a bit this morning after Friday's massive selloff. Is that
- 1:28Speaker 1: why we're seeing sort of the move higher for Micron
- 1:31Speaker 1: Technology this morning.
- 1:33Speaker 3: That's it. So Micron ticker MU is up four percent
- 1:36Speaker 3: in the pre market. This was the biggest loser in
- 1:39Speaker 3: the S and P five hundred on Friday, it fell
- 1:42Speaker 3: thirteen percent. But the risk appetite has turned around over
- 1:45Speaker 3: the weekend and signs of an AI selloff are stabilizing
- 1:48Speaker 3: today after a three day route in the Nasdaq one hundred.
- 1:51Speaker 3: We also had Nvidia CEO Jensen Wong calling the dip
- 1:55Speaker 3: in tech stocks a buying opportunity, saying, quote, everybody should
- 1:59Speaker 3: be very excited they can now buy stock at a
- 2:03Speaker 3: cheaper price. And that seems to be what's happening in
- 2:05Speaker 3: the pre market, pushing those shares up and Micron in general.
- 2:08Speaker 3: It's one of the three major memory players, big investment
- 2:12Speaker 3: theme for the AI trade, and the only one in
- 2:15Speaker 3: the US. It's been one of the top contributors to
- 2:17Speaker 3: the s and P five hundred rebound off the march
- 2:19Speaker 3: lows that stock going up again this morning.
- 2:22Speaker 1: Well, one of the most actively traded, if not the
- 2:24Speaker 1: most actively traded stock in this morning's pre market is
- 2:27Speaker 1: Neurix Therapeutics, well away from the tech trade.
- 2:31Speaker 2: Dan.
- 2:32Speaker 3: Yeah, and this is off a bit of news over
- 2:35Speaker 3: the weekend. So Neurox Therapeutics is up five percent in
- 2:37Speaker 3: the pre market ticker and RIX. And this is a
- 2:41Speaker 3: drug maker, and Roche has agreed to pay up to
- 2:44Speaker 3: two point three billion dollars for the rights to Newux's
- 2:47Speaker 3: experimental blood cancer drug. Neworks will receive seven hundred million
- 2:50Speaker 3: dollars up front. Roche and Neuroks will share development costs
- 2:53Speaker 3: and split US profits equally. And this is a drug
- 2:56Speaker 3: Neurox has been working on. It's a new class of
- 2:58Speaker 3: medicine aimed at eliminating a protein that drives several cancers,
- 3:02Speaker 3: and it's en Roche is looking to build out its
- 3:05Speaker 3: cancer portfolio beyond its aging blockbuster medicines, so that giving
- 3:10Speaker 3: Neurex a nice lift in the pre market.
- 3:12Speaker 1: And that's not the only pharmacy stock getting a lift
- 3:14Speaker 1: as well. Eli Lilly shares are on the rise this morning,
- 3:18Speaker 1: so Eli Lilly tick our Lly. Those shares are up
- 3:21Speaker 1: four percent in the pre market. The obese drug maker
- 3:24Speaker 1: presented at the American Diabetes Associated Association conference, and City
- 3:28Speaker 1: analysts say their conviction on Lily is firmly intact. The
- 3:32Speaker 1: portfolio is not built around singular blockbusters, as one of
- 3:35Speaker 1: City's enthusiastic points around it, and it also noted positive
- 3:39Speaker 1: results from a phase two study for a once a
- 3:41Speaker 1: week injectable. We also had some other news in the
- 3:44Speaker 1: drug los space, with competitor Zealand Pharma tumbling over twenty percent.
- 3:48Speaker 1: That company has a potentially competing obesity drug and data
- 3:52Speaker 1: from that study disappointed.
- 3:54Speaker 2: This stock mover's report from Bloomberg Radio. Check back with
- 3:58Speaker 2: us throughout the day for the latest roundup of companies
- 4:01Speaker 2: making news on Wall Street and for the latest market
- 4:04Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 4:09Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto. With
- 4:12Speaker 2: the Bloomberg Business app